NCT00260533View on ClinicalTrials.gov

Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Generalized Social Phobia
Interventions
DRUG

atomoxetine

Flexible dose, up to 50 mg per day

DRUG

placebo

placebo (matching to atomoxetine)

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

University of California, San Diego

OTHER

NCT00260533 - Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder | Biotech Hunter | Biotech Hunter